Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: A meta-analysis Peter Donndorf, MD, Guenther Kundt, PhD,

Slides:

Advertisements

Similar presentations

The “occasional open heart surgeon” revisited

Advertisements

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

Total arterial revascularization of triple vessel coronary disease based on combined internal thoracic and radial artery grafts Robert H. Habib, PhD,

Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational.

Percutaneous coronary invervention versus coronary artery bypass grafting: A meta- analysis Yolba Smit, MD, MSc, Joan Vlayen, MD, Hetty Koppenaal, MD,

Pre-existing psychological depression confers increased risk of adverse cardiovascular outcomes following cardiac surgery: A systematic review and meta-analysis

Proteinuria predicts postcardiotomy acute kidney injury in patients with preserved glomerular filtration rate Szu-Yuan Li, MD, Chiao-Lin Chuang, MD,

Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: Safety and efficacy studies

The impact of placing multiple grafts to each myocardial territory on long-term survival after coronary artery bypass grafting Danny Chu, MD, Faisal.

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

Long-term efficacy and safety of the intramyocardial implantation of autologous bone marrow cells for the treatment of ischemic heart disease Tao-Sheng.

The American Association for Thoracic Surgery 2016 Ethics Forum: Cost-effectiveness and the ethics of left ventricular assist device therapy John W.C.

Do higher-risk patients benefit from off-pump coronary artery bypass grafting? Evidence from an ecologic analysis of randomized trials Oliver Kuss, PhD,

Outcomes of coronary artery bypass grafting in patients with inflammatory rheumatic diseases: An 11-year nationwide cohort study Chao-Han Lai, MD, PhD,

Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis

Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies Hisato Takagi,

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

CD133+ cells: How could they have an IMPACT?

Right internal thoracic artery or saphenous vein grafting

Which is more important in the potential interference on cardioprotection by remote ischemic preconditioning: β-blockers or anesthetic choice? Yang Liu,

Intrinsic cardiac stem cells are essential for regeneration

Juan A. Crestanello, MD, Richard C. Daly, MD

Coronary artery bypass grafting is superior to first-generation drug-eluting stents for unprotected left main coronary artery disease: An updated meta-analysis.

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Lower graft patency after off-pump than on-pump coronary artery bypass grafting: An updated meta-analysis of randomized trials Hisato Takagi, MD, PhD,

A randomized comparison of the Saphenous Vein Versus Right Internal Thoracic Artery as a Y-Composite Graft (SAVE RITA) trial: Early results Ho Young.

Why surgery won the SYNTAX trial and why it matters

Hisato Takagi, MD, PhD, Takuya Umemoto, MD, PhD

Zhe Zheng, MD, PhD, Heng Zhang, MD, PhD, Bo Xu, MBBS

Coronary artery bypass in patients with type 2 diabetes: Experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial Edward.

Multilevel data analysis: What? Why? How?

How should we treat air leaks?

Harold L. Lazar, MD The Journal of Thoracic and Cardiovascular Surgery

Long-term results of simultaneous carotid endarterectomy and myocardial revascularization with cardiopulmonary bypass used for both procedures Kazutomo.

Effect of statins on atrial fibrillation after cardiac surgery: A duration- and dose-response meta-analysis Wendy T. Chen, PharmD, Guru M. Krishnan,

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Surgical economics: MACRA, MIPS, and bundles—Lessons learned in the first 3 years of a coronary artery bypass grafting alternative payment model Daniel.

Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation David.

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Performance of the European System for Cardiac Operative Risk Evaluation II: A meta- analysis of 22 studies involving 145,592 cardiac surgery procedures

Angiographic outcomes of radial artery versus saphenous vein in coronary artery bypass graft surgery: A meta-analysis of randomized controlled trials

Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?

Innovation and science: The future of valve design

Yin-Shu Chang, MD, Jia-Xiang Wang, MD, PhD, Da-Wei Chang, PhD

For everything there is a season

A first start for lung transplantation?

Niv Ad, MD, Sari D. Holmes, PhD, Paul S. Massimiano, MD, Anthony J

Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease Neuza Helena Lopes, MD, PhD, Felipe da Silva Paulitsch, MD,

To bypass or stent? The changing rules of an advancing game

Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: A meta-analysis of randomized and nonrandomized.

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: A.

Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass Benjamin Medalion, MD, Michael G. Katz, MD,

Long-term survival in lung transplant recipients after successful preoperative coronary revascularization Leonardo Seoane, MD, Lee M. Arcement, MD, Vincent.

Hisato Takagi, MD, PhD, Takuya Umemoto, MD, PhD

Ralph S. Mosca, MD The Journal of Thoracic and Cardiovascular Surgery

Meta-analysis of randomized trials on the efficacy of posterior pericardiotomy in preventing atrial fibrillation after coronary artery bypass surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Improved quality and cost-effectiveness of coronary artery bypass grafting in the United States from 1988 to 2005 Howard K. Song, MD, PhD, Brian S. Diggs,

The continuing challenge of congenital heart disease in China

Right internal thoracic artery versus radial artery as the second best arterial conduit: Insights from a meta-analysis of propensity-matched data on long-term.

Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know Harold L. Lazar,

National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements Abby J. Isaacs, MS, Jeffrey Shuhaiber,

Impact of preoperative left ventricular function and time from infarction on the long-term benefits after intramyocardial CD133+ bone marrow stem cell.

Comparing microvascular alterations during minimal extracorporeal circulation and conventional cardiopulmonary bypass in coronary artery bypass graft.

Presentation transcript:

Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: A meta-analysis Peter Donndorf, MD, Guenther Kundt, PhD, Alexander Kaminski, MD, Can Yerebakan, MD, Andreas Liebold, MD, PhD, Gustav Steinhoff, MD, PhD, Aenne Glass The Journal of Thoracic and Cardiovascular Surgery Volume 142, Issue 4, Pages 911-920 (October 2011) DOI: 10.1016/j.jtcvs.2010.12.013 Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Flow chart of eligible studies with BMSC transplantation in combination with CABG in patients with chronic ischemic heart disease. CABG, Coronary artery bypass grafting; RCT, randomized controlled trial. The Journal of Thoracic and Cardiovascular Surgery 2011 142, 911-920DOI: (10.1016/j.jtcvs.2010.12.013) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Forest plot of difference in mean with 95% CI shows improvement of LVEF (Mean difference LVEFchange) in patients treated with BMSC compared with control group. Transplantation of BMSC in addition to CABG resulted in a 5.40% (95% CI, 1.36–9.44) increase in mean LVEF. The overall effect was statistically significant in favor of BMSC therapy. Sizes of data markers represent the statistical weight each study contributed to the overall random-effects estimate. Heterogeneity: χ2 = 27.28, df = 5, P < .001, and I2 (variation in weighted mean difference attributable to heterogeneity) = 81.7%; significant overall effect: z = 2.62, P = .009. The Journal of Thoracic and Cardiovascular Surgery 2011 142, 911-920DOI: (10.1016/j.jtcvs.2010.12.013) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Forest plot of difference in mean with 95% CI shows change of LVEDV (Mean difference LVEDVchange) in patients treated with BMSC compared with control groups. BMSC transplantation in addition to CABG resulted in a 9.55-mL (95% CI, −2.81 to 21.92) decrease in mean LVEDV. The overall effect favors BMSC treatment (not significant). Sizes of data markers represent the statistical weight each study contributed to the overall fixed-effects estimate. No heterogeneity: χ2 = 1.45, df = 2, P = .485, and I2 (variation in weighted mean difference attributable to heterogeneity) = 0.0%; significant overall effect: z = 1.51, P = .130. The Journal of Thoracic and Cardiovascular Surgery 2011 142, 911-920DOI: (10.1016/j.jtcvs.2010.12.013) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Forest plot of RR with the corresponding 95% CI for ventricular arrhythmias in patients treated with BMSC compared with control group. Sizes of data markers represent the statistical weight each study contributed to the overall fixed-effects estimate. The overall RR shows no significant difference between the 2 groups (RR = 0.951, 95% CI, 0.389–2.325, z = −0.109, P = .913), and the included studies are not to be considered inhomogeneous concerning ventricular arrhythmias (χ2 = 1.122, df = 5, P = .952). The Journal of Thoracic and Cardiovascular Surgery 2011 142, 911-920DOI: (10.1016/j.jtcvs.2010.12.013) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Figure 5 Forest plot of RR with the corresponding 95% CI for the composite of other cardiovascular events (cardiac death, recurrent myocardial infarction, additional coronary revascularization procedures, and stroke) in patients treated with BMSC compared with control group. Sizes of data markers represent the statistical weight each study contributed to the overall fixed-effects estimate. The overall RR shows no significant difference between the 2 groups (RR = 1.134, 95% CI, 0.28–4.599, z = 0.176, P = .86), and the included studies are not to be considered inhomogeneous concerning the composite of other cardiovascular events (χ2 = 1.504, df = 5, P = .913). The Journal of Thoracic and Cardiovascular Surgery 2011 142, 911-920DOI: (10.1016/j.jtcvs.2010.12.013) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions